MIAMI, FL / ACCESSWIRE / February 29, 2016 / Top Nasdaq Stocks is issuing a report on three stocks to watch VBIV, AMBS, RXMD & the iShares Nasdaq Biotechnology (IBB) fund. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
VBI Vaccines (Nasdaq: VBIV) is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. VBI's eVLP Platform allows for the design of enveloped virus-like particle vaccines that closely mimic the target virus. VBI's lead eVLP asset is a prophylactic cytomegalovirus vaccine; VBI has initiated work for GMP manufacturing of its CMV candidate for use in formal preclinical and Phase I trials. VBI's second platform is a thermostable technology that enables the development of vaccines and biologics that can preserve vaccine potency and withstand storage or shipment at fluctuating temperatures. Sign Up to Receive Top Rated Small Cap NASDAQ Alerts With Strong Upside Potential. Shares of the Company are trading higher today than they were less 1 week ago. Subscribe To Our Free Email List & Get More Info on VBI Vaccines (Nasdaq: VBIV).
Enjoy picks like this? Get These Alerts and More on NASDAQ Companies before They Rally, Text the word "NASDAQ" to 77948
Amarantus Bioscience Holdings, Inc(OTCQX: AMBS)Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostics and therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, and ophthalmological disorders. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with relapsing-remitting multiple sclerosis at first clinical presentation. Its therapeutic products in development comprise Eltoprazine, a small molecule drug that is in Phase II clinical trials for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and adult attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including iretinitis pigmentosa, Parkinson's disease, cardiac ischemia, and stroke. It is also developing NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson's disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University to develop its full thickness skin replacement product. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus Bioscience Holdings, Inc. in April 2013. Amarantus Bioscience Holdings, Inc. was founded in 2008 and is based in San Francisco, California.Subscribe To Our Free Email List & Get More Info on Amarantus Bioscience, Inc. (AMBS)
Enjoy picks like this? Get These Alerts and More on NASDAQ Companies before They Rally, Text the word "NASDAQ" to 77948
Progressive Care, Inc. (OTC: RXMD)is an international biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the cardiovascular, neurological, inflammatory and immune disease areas, and has several ongoing clinical trials evaluating this potential regenerative medicine product. The stock has seen considerable volume and price appreciation in less than 2 months; increasing by as much as an addition $1 per share at times in comparison to previous prices in January. Subscribe To Our Free Email List & Get More Info on Progressive Care, Inc. (RXMD).
iShares Nasdaq Biotechnology (NASDAQ: IBB) this fund saw a dip earlier last week and on Tuesday 2/24 the (IBB) began to bounce back up towards previous highs, indicating that the biotech sector is on the rise as we begin this week. The (IBB) seeks to track the investment results of the NASDAQ Biotechnology Index, which contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by NASDAQ OMX. The fund generally invests at least 90% of its assets in securities of the index and in depositary receipts representing securities of the index. It may invest the remainder of its assets in certain futures, options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Stay Informed and Up To Date On The Hottest NASDAQ Plays. Get Them Here
About TopNasdaqStocks.com
Looking for stock market and business news headlines? How about up to the minute information on mutual funds and ETFs? Don't forget about the top stock picks of 2016. TopNasdaqStocks.com has it all. Make sure to subscribe to our free newsletter and to receive free text message alerts on your phone, text "NASDAQ" to 77948.
Disclosure: The information, opinions and analysis contained in this report are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We do not accept any responsibility or liability for any losses, damages or costs arising from an investor's or other person's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities, nor a recommendation of any security. Past gains are not representative of future gains. Top Nasdaq Stocks has not been compensated nor does it expect to receive any compensation for distribution of its opinions and publicly available information regarding the companies reported in this investment opinion article at this time. The opinions contained herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. When used herein, the words "anticipate," "intend," "estimate," "believe," "expect," "plans," "should," "potential," "forecast," and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A company's actual results could differ materially from those described in any forward-looking statements contained herein. Top Nasdaq Stocks is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. We recommend that you use the information found herein as an initial starting point for conducting your own research in order to determine your own personal opinion of the companies discussed herein before deciding whether or not to invest. You should seek such investment, tax, financial, accounting or legal advice appropriate for your particular circumstances. Information about many publicly traded companies and other investor resources can be found at www.sec.gov. Investing in securities is speculative and carries risk. Please visit http://topnasdaqstocks.com/index.php/disclaimer/ website for a more detailed discussion of risks and disclosures.
Contact:
Top Nasdaq Stocks
news@topnasdaqstocks.com
SOURCE: Top Nasdaq Stocks
